Companies · Biotechnology

Spinal Simplicity, LLC

Overland Park · Biotechnology

Diligence memoA one-page analyst read on Spinal Simplicity, LLC — recommendation, valuation, rhythm, risks.
$21.1M
Total raised · real
5
Rounds
27.1×
Latest step-up
Top 33%
Sector rank · raised
Series A
Latest stage · inferred · Thu Dec 12 2024 00:00:00 GMT+0000 (Coordinated Universal Time)

Spinal Simplicity, LLC looks under-valued against its niche peers and is quiet on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the biotech sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Under-valued
  • Modeled value is 0.58× the median modeled value of Series A Biotechnology companies in 2022–2024 (303 peers) — value vs value, same stage and era.
Quiet
  • Last raise 19 mo ago; this sector typically re-raises about every 14 months.
  • Slightly overdue versus sector cadence.

Procedural diagnosis est. — rule-based common-sense checks over the filing pattern, issuer name, activity cadence, and surfaced operating evidence.

Issuer-vehicle patternmedium confidence

Spinal Simplicity, LLC behaves more like a recurring private-offering issuer than a conventional venture-backed operating company.

Issuer structure
Company-like
No recurring-offering pattern strong enough to override normal financing interpretation.
Lifecycle
15.6 yr record
Peak capital year was 2021 with $11.2M across 2 filings.
Market position
ahead of 68% of Biotechnology peers
Capital scale is ahead of 68% of Biotechnology peers; modeled value is above 32% of peers by modeled value. Large capital with mid-pack modeled value can signal an issuer/program profile rather than operating-company growth.
Valuation reliability
Normal applicability
Stage/dilution valuation models are weakest when the issuer is broad-sector, recurring, or vehicle-like.
Operating evidence
Sparse
No clear CEO/founder/principal role is surfaced, so operating-company confidence is lower.
Data quality
Needs review
Row-level filing totals differ from canonical totals, so amendment/superseded filtering should be checked.
What triggered this
  • Legal name looks like an issuer vehicle rather than a product company.
  • No clearly named CEO/founder/principal role in the public records surfaced here.
  • No verified homepage on the profile yet.
  • Capital program peaked in 2021: $11.2M across 2 filings.
  • Largest single filing was $10.9M on 2021-05-11.
  • Filing rows sum to $23.7M, while canonical raised total is $21.1M; likely amendments/superseded rows are mixed into the detail view.
How to read the page
  • Read this less like a startup funding journey and more like a capital-raising program.
  • Stage-based valuation and peer labels have lower applicability for this pattern.
  • The more important signal is lifecycle: repeated filings ended years ago, so current activity needs outside confirmation.
  • Canonical filtering should be tightened before using row-level totals for diligence.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Biotechnology

Spinal Simplicity, LLC is one of 4293 Biotechnology companies tracked from Overland Park. By capital raised it ranks mid-pack (ahead of 68% of sector peers), and in the long tail by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
Rule 506(b)
Reg D exemption
27
Investors (latest)
2024-12-12
First sale
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$125M$250M$375M$500MPre-Seed · 2010-11-22 Raised $704K (real) Modeled valuation $39M (est)Pre-Seed2010Seed · 2010-11-22 Raised $2.4M (real) Modeled valuation $109M (est)Seed2010Seed · 2013-01-23 Raised $1.4M (real) Modeled valuation $63M (est)Seed2013Seed · 2013-01-23 Raised $1.4M (real) Modeled valuation $63M (est)Seed2013Seed · 2014-10-17 Raised $250K (real) Modeled valuation $11M (est)Seed2014Pre-Seed · 2021-05-11 Raised $349K (real) Modeled valuation $11M (est)Pre-Seed2021Series A · 2021-05-11 Raised $11M (real) Modeled valuation $259M (est)Series A2021Pre-Seed · 2024-12-12 Raised $225K (real) Modeled valuation $786K (est)Pre-Seed2024Series A · 2024-12-12 Raised $6.1M (real) Modeled valuation $26M (est)Series A2024+$2.4M+$1.4M+$1.4M+$250K+$349K+$11M+$225K+$6.1MCumulative $24M

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Pre-Seed$704K · 2010
Seed$2.4M · 2010
Seed extension$1.4M · 2013
Seed extension$1.4M · 2013
Seed extension$250K · 2014
Bridge · Seed-stage$349K · 2021smaller follow-on
Series A$10.9M · 2021
Bridge · Series A-stage$225K · 2024smaller follow-on
Series A extension$6.1M · 2024

Stages are modeled from round size (public records carry no series label). Ladder is contiguous — every modeled rung has a record.

Modeled valuation trajectory
$25.8M
Base estimate est.
$6.7M
Conservative case
$50.3M
Upside case
$27.7M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Series Aa $4.0M–$15M round). Valuation is modeled from stage benchmarks scaled by the biotech sector profile. Directional, not a quoted figure.

Pre-Seed · modeled $38.8M · 2010-11-222010Seed · modeled $108.6M · 2010-11-22Seed · modeled $62.6M · 2013-01-23Seed · modeled $62.6M · 2013-01-23Seed · modeled $11.1M · 2014-10-17Pre-Seed · modeled $11.3M · 2021-05-11Series A · modeled $259.4M · 2021-05-11Pre-Seed · modeled $786K · 2024-12-12Series A · modeled $25.8M · 2024-12-122024
Model inputs · modeled:benchmark-stage-stepup-v1
22%
Dilution assumption
Implied ownership sold in the financing.
44%
Survival probability
24% low · 60% high
1.62×/yr
Annual markup
2.04×/yr upside case
1.6 yr
Elapsed time used
1.6 yr actual, capped for stale marks
biotech
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
21 mo
Avg between rounds
$1.5M/yr
Capital velocity
15.6 yr
On record since
2010
First round
9
Rounds on file
How it compares to the market

Benchmarked against 4293 companies in Biotechnology. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 2.9× above median
This company$21.1M
Sector median$7.2M
Latest round — vs other Series A rounds in sector (real $, this stage) 1.1× above median
This company$6.1M
Sector median$5.4M
Modeled value — vs sector median (estimate, all stages) 0.4× of median
This company$25.8M
Sector median$64.2M

Raised more than 68% of sector peers (real $). Modeled value above 32% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Series A) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #219 of 303.

This companyCohort peer
$10.0M$100.0M$1.0B$10.0M$100.0MCapital raised (log)GeoVax Labs, Inc. · Series A Raised $39.1M · modeled $217.3M (est)Cellinfinity Bio Holding Company, LLC · Series A Raised $13.2M · modeled $216.2M (est)Adient Medical, Inc. · Series A Raised $18.2M · modeled $207.1M (est)Entegrion Inc · Series A Raised $22.7M · modeled $191.5M (est)BCD Bioscience, Inc. · Series A Raised $16.4M · modeled $189.2M (est)Pragma Biosciences Inc. · Series A Raised $14.5M · modeled $186.2M (est)MicroByre, Inc. · Series A Raised $16.1M · modeled $185.9M (est)Cardiac Insight, Inc. · Series A Raised $38.1M · modeled $184.0M (est)Cardiac Implants LLC · Series A Raised $13.5M · modeled $178.4M (est)Abintus Bio, Inc. · Series A Raised $13.7M · modeled $177.4M (est)Mosaic Biosciences, Inc. · Series A Raised $14.7M · modeled $176.4M (est)Mazen Animal Health Inc. · Series A Raised $13.5M · modeled $169.0M (est)Spinal Simplicity, LLC (this company) Raised $21.1M · modeled $25.8M (est)Spinal Simplicity, LLC
CompanyStageRaised · realValue · estvs peer med.
GeoVax Labs, Inc.Series A$39.1M$217.3M4.90×
Cellinfinity Bio Holding Company, LLCSeries A$13.2M$216.2M4.87×
Adient Medical, Inc.Series A$18.2M$207.1M4.67×
Entegrion IncSeries A$22.7M$191.5M4.32×
BCD Bioscience, Inc.Series A$16.4M$189.2M4.27×
Pragma Biosciences Inc.Series A$14.5M$186.2M4.20×
MicroByre, Inc.Series A$16.1M$185.9M4.19×
Cardiac Insight, Inc.Series A$38.1M$184.0M4.15×
Cardiac Implants LLCSeries A$13.5M$178.4M4.02×
Abintus Bio, Inc.Series A$13.7M$177.4M4.00×
Mosaic Biosciences, Inc.Series A$14.7M$176.4M3.98×
Mazen Animal Health Inc.Series A$13.5M$169.0M3.81×
Spinal Simplicity, LLC this companySeries A$21.1M$25.8M0.58×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Pre-Seed$704K2010-11-22$3.9M$38.8M85%
Seed$2.4M2010-11-22$12.2M$108.6M85%
Seed$1.4M2013-01-23$7.0M$62.6M85%
Seed$1.4M2013-01-23$7.0M$62.6M85%
Seed$250K2014-10-17$1.3M$11.1M85%
Pre-Seed$349K2021-05-11$1.9M$11.3M90%
Series A$10.9M2021-05-11$49.3M$259.4M90%
Pre-Seed$225K2024-12-12$1.3M$786K90%
Series A$6.1M2024-12-12$27.7M$25.8M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Pre-Seed$704K2010-11-22
    • First recorded raise — entered as Pre-Seed.
    • 11 investors on this round.
  2. Seed$2.4M2010-11-22
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round 3.5× larger than the prior — scaling up.
    • Revenue band moved No revenue → $0–$1M.
    • 30 investors on this round.
  3. Seed$1.4M2013-01-23
    • Raised again after 26 mo — slower than the ~14 mo sector norm.
    • Round 1.7× smaller than the prior — bridge or down round.
    • Switched to Rule 506(b) (was Rule 06).
    • 25 investors on this round.
  4. Seed$1.4M2013-01-23
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round roughly the size of the prior one.
    • 25 investors on this round.
  5. Seed$250K2014-10-17
    • Raised again after 21 mo — slower than the ~14 mo sector norm.
    • Round 5.6× smaller than the prior — bridge or down round.
    • 3 investors on this round.
  6. Pre-Seed$349K2021-05-11
    • Raised again after 79 mo — slower than the ~14 mo sector norm.
    • Round 1.4× larger than the prior — scaling up.
    • 5 investors on this round.
  7. Series A$10.9M2021-05-11
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round 31.1× larger than the prior — scaling up.
    • 80 investors on this round.
  8. Pre-Seed$225K2024-12-12
    • Raised again after 43 mo — slower than the ~14 mo sector norm.
    • Round 48.2× smaller than the prior — bridge or down round.
    • 2 investors on this round.
  9. Series A$6.1M2024-12-12
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round 27.1× larger than the prior — scaling up.
    • 27 investors on this round.
Intelligence
2026 ~Q3
Modeled next raise · ~21mo cadence
$18.3M
Modeled next size est.range $11.9M$29.3M
27.1×
Last step-up
$1.5M/yr
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
Harold Hess1 other2010-11
Jonathan Hess2010-11
Julie Mckee2013-01
Tim McCown2021-05
Todd Moseley2010-11
Registry & provenance

Spinal Simplicity, LLC is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1507286
SEC CIK
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
Cellibre, Inc.BiotechnologySeries A$20.8M$31.2Msame sector · same stage
Andrew Technologies LLCBiotechnologySeries A$21.8M$26.7Msame sector · same stage
Meadowhawk Biolabs, Inc.BiotechnologySeries A$20.3M$26.3Msame sector · same stage
Ineedmd,Inc.BiotechnologySeries A$22.0M$30.0Msame sector · same stage
ABT Molecular Imaging, Inc.BiotechnologySeries A$19.9M$27.1Msame sector · same stage
Imbed Biosciences, IncBiotechnologySeries A$22.3M$23.9Msame sector · same stage
Dracen Pharmaceuticals, Inc.BiotechnologySeries A$19.4M$20.0Msame sector · same stage
Neurovance, Inc.BiotechnologySeries A$23.0M$20.0Msame sector · same stage
Semantically similar

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

CompanySectorStageValue · estMatch
Spinal Balance, Inc.BiotechnologySeries A$155.1M92%
Spineology IncBiotechnologySeries B$35.0M89%
Neuro Spine Ventures, LLCBiotechnologyPre-Seed$1.8M89%
Additive Spine, LLCBiotechnologyPre-Seed$12.7M88%
Spinal Singularity, Inc.BiotechnologySeed$88.6M88%
Intralink Spine, Inc.BiotechnologyPre-Seed$44.2M84%
Bone Health Technologies, Inc.BiotechnologySeed$29.8M83%
Aegis Spine, Inc.BiotechnologySeed$35.6M83%
Frequently asked
How much funding has Spinal Simplicity, LLC raised?
Spinal Simplicity, LLC has raised approximately $21.1M in disclosed capital across 5 recorded financing rounds, aggregated from public filings.
What is Spinal Simplicity, LLC's estimated valuation?
Provath's modeled valuation for Spinal Simplicity, LLC is approximately $25.8M (modeled range $6.7M–$50.3M). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is Spinal Simplicity, LLC at?
Spinal Simplicity, LLC's latest modeled financing stage is Series A. Its most recent recorded round closed around Thu Dec 12.
What does Spinal Simplicity, LLC do and where is it based?
Spinal Simplicity, LLC operates in the Biotechnology sector, based in Overland Park.
Explore related

See where Spinal Simplicity, LLC sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at Spinal Simplicity, LLC, claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.